213 related articles for article (PubMed ID: 29305787)
1. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
Michaelsen SR; Urup T; Olsen LR; Broholm H; Lassen U; Poulsen HS
J Neurooncol; 2018 May; 137(3):533-542. PubMed ID: 29305787
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain.
Geisenberger C; Mock A; Warta R; Rapp C; Schwager C; Korshunov A; Nied AK; Capper D; Brors B; Jungk C; Jones D; Collins VP; Ichimura K; Bäcklund LM; Schnabel E; Mittelbron M; Lahrmann B; Zheng S; Verhaak RG; Grabe N; Pfister SM; Hartmann C; von Deimling A; Debus J; Unterberg A; Abdollahi A; Herold-Mende C
Acta Neuropathol; 2015 Sep; 130(3):419-34. PubMed ID: 25931051
[TBL] [Abstract][Full Text] [Related]
3. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
[TBL] [Abstract][Full Text] [Related]
5. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
6. Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.
Lu J; Cowperthwaite MC; Burnett MG; Shpak M
PLoS One; 2016; 11(4):e0154313. PubMed ID: 27124395
[TBL] [Abstract][Full Text] [Related]
7. Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma.
Beig N; Patel J; Prasanna P; Hill V; Gupta A; Correa R; Bera K; Singh S; Partovi S; Varadan V; Ahluwalia M; Madabhushi A; Tiwari P
Sci Rep; 2018 Jan; 8(1):7. PubMed ID: 29311558
[TBL] [Abstract][Full Text] [Related]
8. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.
Sommerlath VN; Buergy D; Etminan N; Brehmer S; Reuss D; Sarria GR; Guiot MC; Hänggi D; Wenz F; Petrecca K; Giordano FA
Radiat Oncol; 2022 Jan; 17(1):15. PubMed ID: 35073955
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).
Grunda JM; Nabors LB; Palmer CA; Chhieng DC; Steg A; Mikkelsen T; Diasio RB; Zhang K; Allison D; Grizzle WE; Wang W; Gillespie GY; Johnson MR
J Neurooncol; 2006 Dec; 80(3):261-74. PubMed ID: 16773218
[TBL] [Abstract][Full Text] [Related]
10. Integrated genomic analysis of survival outliers in glioblastoma.
Peng S; Dhruv H; Armstrong B; Salhia B; Legendre C; Kiefer J; Parks J; Virk S; Sloan AE; Ostrom QT; Barnholtz-Sloan JS; Tran NL; Berens ME
Neuro Oncol; 2017 Jun; 19(6):833-844. PubMed ID: 27932423
[TBL] [Abstract][Full Text] [Related]
11. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
12. Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.
Ahmadipour Y; Jabbarli R; Gembruch O; Pierscianek D; Darkwah Oppong M; Dammann P; Wrede K; Özkan N; Müller O; Sure U; El Hindy N
World Neurosurg; 2019 Feb; 122():e461-e466. PubMed ID: 30347300
[TBL] [Abstract][Full Text] [Related]
13. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival?
Adeberg S; Bostel T; König L; Welzel T; Debus J; Combs SE
Radiat Oncol; 2014 Apr; 9():95. PubMed ID: 24758192
[TBL] [Abstract][Full Text] [Related]
14. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme.
Martinez R; Schackert G; Esteller M
J Neurooncol; 2007 Apr; 82(2):133-9. PubMed ID: 17048097
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
Biswas A; Salvucci M; Connor K; Düssmann H; Carberry S; Fichtner M; King E; Murphy B; O'Farrell AC; Cryan J; Beausang A; Heffernan J; Cremona M; Hennessy BT; Clerkin J; Sweeney KJ; MacNally S; Brett F; O'Halloran P; Bacon O; Furney S; Verreault M; Quissac E; Bielle F; Ahmed MH; Idbaih A; Leenstra S; Ntafoulis I; Fabro F; Lamfers M; Golebiewska A; Hertel F; Niclou SP; Yen RTC; Kremer A; Dilcan G; Lodi F; Arijs I; Lambrechts D; Purushothama MK; Kel A; Byrne AT; Prehn JHM
J Neurooncol; 2023 Jun; 163(2):327-338. PubMed ID: 37237151
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
19. Chemokine receptor CXCR7 is an independent prognostic biomarker in glioblastoma.
Deng L; Zheng W; Dong X; Liu J; Zhu C; Lu D; Zhang J; Song L; Wang Y; Deng D
Cancer Biomark; 2017 Jul; 20(1):1-6. PubMed ID: 28759950
[TBL] [Abstract][Full Text] [Related]
20. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
